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M I C R O B I O L O G Y
A VersaTile-driven platform for rapid hit-to-lead 
development of engineered lysins
H. Gerstmans1,2,3, D. Grimon1, D. Gutiérrez1,4, C. Lood2,5, A. Rodríguez4, V. van Noort5,6, 
J. Lammertyn3, R. Lavigne2, Y. Briers1*
Health care authorities are calling for new antibacterial therapies to cope with the global emergence of antibiotic- 
resistant bacteria. Bacteriophage-encoded lysins are a unique class of antibacterials with promising (pre)clinical 
progress. Custom engineering of lysins allows for the creation of variants against potentially any bacterial patho-
gen. We here present a high-throughput hit-to-lead development platform for engineered lysins. The platform is 
driven by VersaTile, a new DNA assembly method for the rapid construction of combinatorial libraries of engi-
neered lysins. We constructed approximately 10,000 lysin variants. Using an iterative screening procedure, we 
identified a lead variant with high antibacterial activity against Acinetobacter baumannii in human serum and an 
ex vivo pig burn wound model. This generic platform could offer new opportunities to populate the preclinical 
pipeline with engineered lysins for diverse (therapeutic) applications.
INTRODUCTION
The rapid emergence and spread of multi- and extensively drug- 
resistant bacteria are a major public health threat that is further ex-
acerbated by the lack of novel antibiotics. Projections made by the 
World Health Organization indicate that antibiotic-resistant bacteria 
may be responsible for more than 10 million deaths by 2050, thereby 
outnumbering cancer-related deaths, if no global action is undertaken 
(1). The once successful Waksman platform, mining natural anti-
biotics from soil-derived actinomycetes, heralded the golden era of 
antibiotic discovery during the 1940s to 1960s. However, the Waksman 
platform increasingly led to the rediscovery of the same classes of 
antibiotics (2). The diminishing success spurred the pharmaceutical 
industry to establish new discovery platforms. With the emergence 
of genomics in the 1990s, the focus shifted to high-throughput 
screening campaigns of large libraries of synthetic compounds 
against essential and conserved bacterial targets. Although lead 
compounds were identified, they failed under in vivo conditions. 
One of the main causes was the lack of penetration into bacterial 
cells (3). This critical shortcoming was most pronounced in the case 
of Gram-negative pathogens due to their outer membrane (2, 4). 
This approach resulted in a disappointing and financially unsus-
tainable outcome, contributing to the declining interest in antibiotic 
discovery by the pharmaceutical industry (4). For more than 50 years, 
no new antibiotic classes have been introduced.
New discovery platforms are therefore needed to identify lead 
antibacterials to expand the portfolio of antibiotics. Nonconventional 
approaches that differ from the classic small-molecule antibiotics 
are increasingly considered, both as prophylactics and as therapeutics: 
antibodies, probiotics, natural and engineered bacteriophages, 
immune stimulation, vaccines, peptides, and lysins. A recent pipeline 
portfolio review of antibacterials identified seven (pre)clinical lysin 
projects and underscored the need for further basic research to 
expand the therapeutic options of lysins (5). Lysins are peptidoglycan- 
degrading enzymes produced by (bacterio)phages, including 
endolysins and virion-associated peptidoglycan hydrolases (VAPGHs). 
Owing to immense abundance of phage, the reservoir of lysins 
appears inexhaustible, with candidates against any potential pathogen 
(6). The first lysins targeting Staphylococcus aureus (CF-301, SAL200, 
P128, and Staphefekt™) are currently being evaluated in clinical 
trials (7, 8). Given the typical attrition rates during clinical evalua-
tion and for a guaranteed translation into new therapies against 
a diversity of pathogens, a higher number of candidates under 
clinical evaluation are desired (5). Thus, a reliable and robust dis-
covery platform for efficient lysins is needed.
While wild-type lysins are highly promising, protein engineering 
offers many opportunities to increase this natural diversity. Direct-
ed evolution by protein engineering resulted in engineered lysins 
with improved features toward their specific applications. Besides 
mutagenesis, recombination of the modular domains of lysins has 
been, by far, the most popular approach, as recently reviewed by our 
group (7). Recombination of cell wall binding (CBD) and enzymat-
ic activity domains (EADs) has been used to alter the specificity or 
to improve the activity, stability, and solubility of lysins. A library of 
174 natural, recombined, and truncated variants of lysins and other 
bacterial peptidoglycan hydrolases was screened for optimal activi-
ty against S. aureus in milk (9). Another library of 126 combinatorial 
constructs was used to develop a chimeric lysin with activity against 
planktonic and biofilm methicillin-resistant S. aureus (10). To 
expand the potential of lysins to include killing of Gram-negative 
pathogens, specific outer membrane permeabilizing peptides (OMPs) 
were fused to lysins in a proper way for transfer across the outer 
membrane, resulting in peptidoglycan degradation and death due 
to osmotic lysis (11–14). These engineered lysins are also known as 
Artilysins® (Lysando AG). In a previous study, we created a library of 
49 variants using classic restriction-ligation protocols. Each variant 
was composed of a combination of at least one OMP, a linker, one 
CBD, and one EAD. We concluded that each component affects the 
antibacterial activity but that further empirical research is needed to 
find the best combination for targeting a specific species (12).
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On the basis of the huge diversity of OMPs, linkers, CBDs, and 
EADs, libraries of much higher complexity targeting any pathogen 
can be envisioned. Yet, this progress is impeded by the cumber-
some, time-consuming, and labor-intensive molecular techniques 
to create such modular libraries because methods for combinatorial 
assembly of nonhomologous sequences (such as OMPs, linkers, 
CBDs, and EADs) within an open reading frame are inexistent (15). 
To identify the best engineered lysins from the practically infinite 
sequence space of combinatorially shuffled lysins, we describe here 
a discovery platform to perform design, build, test, and learn cycles 
for engineered lysins in a short period of time. VersaTile drives this 
platform as a new technique to construct a practically unlimited 
number of shuffled lysin sequences. Because an outrageous number 
of variants were created, an iterative search strategy to establish a 
hit-to-lead development process was implemented, similar to the 
lead development of classic pharmaceutical drugs (16). As a proof 
of concept, we here show the use of this discovery platform to iden-
tify a lead lysin variant with broad activity against multidrug-resistant 
Acinetobacter baumannii strains in human serum. We further eval-
uated this lead variant in an ex vivo model of burn wound infection 
to assess its effects on biofilm formation on biological skin-based 
surfaces. The established platform is generic in nature and rep-
resents a discovery platform to identify efficient, engineered lysins 
targeting a broad diversity of pathogens.
RESULTS
Development of a discovery platform for high-throughput 
engineering and testing of lysins
The platform basically consists of three steps that can be iteratively 
repeated (Fig. 1A): (i) designing and building a library of engi-
neered lysins using VersaTile, (ii) expressing engineered lysins in 
parallel and testing their antimicrobial activities, and (iii) learning 
from the output and defining structure-activity relationships. These 
structure-activity relationships can be used to create an enriched 
library with VersaTile as the input for iterative rounds of screen-
ing. To evaluate the performance of this approach, we generated a 
library of approximately 10,000 shuffled lysins to identify the most 
promising lysin variant active against the Gram-negative patho-
gen A. baumannii in human serum.
Integrating previous knowledge to design a smart library 
of engineered lysins
During previous work on lysins targeting Gram-negative bacteria, it 
was observed that both the composition and the specific order of 
the combined modules affect the antibacterial activity of engineered 
lysins. The best results were obtained when using modular lysins 
that comprise both a CBD and an EAD. In addition, an intervening 
linker had a positive effect and the most active variants had an 
N-terminal OMP. Therefore, we designed a library of modular vari-
ants with four positions and the following specific configuration: 
OMP-linker-CBD-EAD. The selected CBD-EAD order resembles 
the natural configuration that is seen in the few modular lysins of 
phages that infect Gram-negative bacteria (12). We have selected 
for each position 38 OMPs, 2 linkers, 6 CBDs, and 21 EADs, respec-
tively (table S1).
The selected OMPs differ in length (between 9 and 44 amino 
acids), fold (helical, sheet, and random coil), cationicity, hydropho-
bicity, and amphipathicity. Some OMPs were designed in silico, 
whereas others have a previously demonstrated outer membrane 
permeabilizing activity. We designed two flexible linkers of differ-
ent length (6 and 14 amino acids). We selected five different CBDs 
from previously characterized modular lysins (KZ, EL, OBP, 
PVP-SE1, and 201phi2-1) (17, 18). These CBDs all directly target 
peptidoglycan with chemotype A1 typical for Gram-negative 
bacteria. In addition, we included a mutagenized variant of the 
CBD of the KZ endolysin, which is no longer able to oligomerize 
through disulfide bridges and which has a higher thermostability 
(11). We selected 21 different EADs, derived from a diversity of 
phages infecting Gram-negative species and with diverse biochemical 
specificities (lysozyme, transglycosylase, amidase, and endopep-
tidase). We used EADs from both globular and modular endolysins 
(table S1).
VersaTile is an efficient method for rapid construction 
of large combinatorial lysin libraries
VersaTile was developed to eliminate the current technical con-
straints to shuffle the modules of engineered lysins in a high-throughput 
manner. VersaTile follows a two-step approach. First, a repository 
of all modules, here called tiles, is constructed. Second, any assem-
bly can be created with these tiles in a directed or random manner 
(Fig. 1B). Therefore, VersaTile is a Lego-like DNA assembly meth-
od specifically for modular proteins such as engineered lysins that 
do not share DNA homology.
A tile is defined here as a coding sequence for a specific module 
(e.g., OMP, linker, CBD, or EAD) that is made compatible for use 
with VersaTile. The coding sequence is therefore flanked by six- 
nucleotide-long position tags and BsaI recognition sites, cloned in a 
dedicated entry vector (pVTE; fig. S1). In total, we created for this 
study a repository with 67 tiles (table S1). Because the lysin design 
consists of four modules (OMP-linker-CBD-EAD), tiles encoding 
OMPs are specifically labeled for position 1, tiles encoding linkers 
for position 2, etc. (table S2). BsaI cleavage within the position tags 
generates position-specific, single-stranded overhangs that are 
joined to generate combinatorial libraries (cyclic digestion and 
ligation using BsaI and T4 DNA ligase, respectively) in a dedicated 
destination vector (pVTD; fig. S1). A combinatorial library was 
constructed with a complexity of 9576 (= 38 × 2 × 6 × 21) variants 
by combining all 38 OMP, 2 linker, 6 CBD, and 21 EAD tiles at their 
respective positions (table S1). In the resulting constructs, adjacent 
modules are separated by a six-nucleotide linker encoding two free-
ly selected amino acids. In this study, only glycine, alanine, and ser-
ine were used (table S2). These flexible amino acids are expected to 
not interfere with the autonomous folding and functioning of the 
modules. The expression of the OMP-linker-CBD-EAD sequences 
in the library is driven by a T7 promotor.
Standard analysis by polymerase chain reaction (PCR) and 
Sanger sequencing of randomly selected clones indicated a correct 
and random assembly with ~95% efficiency. For a comprehensive 
assessment of the representation and randomness of individual tiles 
at each position, we sequenced 30,435 single variants of the combi-
natorial library with nanopore technology as long reads that entirely 
span assembled lysins. We extracted read counts for each individual 
tile and assessed the order of the specific tiles order by leveraging 
the syntenic information contained within the reads. This quality 
control of the library showed that each individual tile is well repre-
sented and can be found in its expected position. Variant counts were 
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were not observed in the sequencing data, without any specific 
patterns of missingness (fig. S2).
Hits are identified through parallel screening of random 
variants for growth inhibition
We implemented parallel protein expression and growth inhibitory 
assessment to screen for hit candidates present within the combina-
torial library (Fig. 1C). Esherichia coli BL21(DE3)-RIL cells were 
transformed with the combinatorial library, and 380 clones were 
randomly picked. The shuffled lysin genes were expressed in parallel 
in 96-deep-well plates. The use of autoinduction medium ensured 
expression induction at the same growth stage of all clones. Lysates 
of all expressed variants were obtained by exposure of the bacteria 
to chloroform vapor. Complete lysis of the cells was confirmed by 
the absence of viable bacteria after spotting the lysates.
We tested these cleared lysates for growth inhibition of four 
different multidrug-resistant A. baumannii strains [106 colony- 
forming units (CFU)/ml]. Seven variants (~2%) showed a complete 
growth inhibition of at least one strain (Table 1). Specifically, 
variant 1D9 completely inhibited all A. baumannii strains tested, 
whereas variant 1G7 was highly active against three strains. The 




Fig. 1. An iterative three-step approach to design, build, test, and analyze engineered lysins. (A) Overview of the three steps of the discovery platform for 
engineered lysins. These steps are iteratively repeated to obtain a lead variant that fulfills the selection criteria. (B) Library of shuffled variants is produced with VersaTile. 
A tile repository of all modules (OMPs, linkers, CBDs, and EADs) is constructed. Each module is cloned into the pVTE vector, flanked with position-specific tags (indicated 
with different colors) and a BsaI recognition site. The restriction site of BsaI is located in the position tag. All tiles from the repository are then mixed per position and 
combined with the pVTD vector for a one-tube combinatorial assembly reaction. After transformation, every clone will have a different assembly of tiles. (C) The variants are 
randomly selected, expressed, and analyzed by a growth inhibitory assay against a panel of four isolates in triplicate. Low optical density indicates a growth inhibitory 
effect. (D) On the basis of the proportional enrichment of specific tiles in the identified hits compared to the nanopore sequenced library, structure-activity relationships 
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one strain (1D1, 1A10, and 1H3), respectively. A. baumannii NCTC 
13423 appeared to be the most susceptible strain, whereas RUH 134 
was only completely inhibited by one variant. The multidrug-resistant 
strains thus showed a variable susceptibility. Spotting the cell 
cultures after 24-hour exposure to these variants confirmed their 
bactericidal effect. All variants also showed muralytic activity 
(Table 1), but no correlation was observed between muralytic and 
growth inhibitory activity.
The active engineered lysins show conserved  
structure-activity relationships
The tile composition of the seven hits was determined by sequenc-
ing to search for structure-activity relationships (Table 1). Some 
tiles were more prevalent at position 1 (OMPs) and position 3 
(CBDs) (Fig. 1D). Specifically, four of seven active variants contain 
a cecropin-related peptide (3× OMP7; 1× OMP11) at position 1. 
Cecropin-related peptides contain a conserved  helix interrupted 
by a hinge (fig. S3) (19), which might be an indicative feature for a 
positive effect related to this type of peptides. Of six possible CBDs, 
four were present. CBD2 and CBD6 were present in the two most 
active hits, respectively, and also most prevalent (threefold and two-
fold, respectively). In addition, CBD6 is a mutagenized derivative of 
the CBD1 of lysin KZ144 (18) and was previously shown to improve 
stability and activity in Art-175 (11). No enrichment of a specific 
linker or EAD was observed.
An iterative combinatorial library screen results 
in an increased ratio of engineered lysins with improved 
and broader efficacy
On the basis of the inferred structure-activity relationships for 
positions 1 and 3, a second, focused library with a complexity of 336 
(4 × 2 × 2 × 21) variants was constructed using VersaTile, reusing 
the tiles from the repository (table S3). For position 1, the number 
of OMPs was reduced from 38 to 4, including only cecropin-related 
peptides (OMP6, OMP7, OMP10, and OMP11). For position 3, 
CBD2 and CBD6 were retained. A number of 188 clones were 
randomly selected, expressed, and analyzed against the same test 
panel of multidrug-resistant strains. The median growth inhibitory 
effect was similar for both libraries, but the distribution of the 
growth inhibitory effects of engineered lysins from the second 
library was consistently broader compared to variants from the first 
library, with both more inferior and superior variants (Fig. 2A). 
Under the same selection criteria as in the first cycle, 40 variants 
showed full growth inhibitory activity against at least one strain, 
significantly increasing the hit rate from 2 to 21% (40 of 188) 
(P < 0.001). This obvious increase in the proportion of active 
engineered lysins is also accompanied by an increase in the number 
of variants that completely inhibited the four strains at the cost of 
variants that only completely inhibited a single strain (Fig. 2B and 
table S4). Both observations support that one or both implemented 
structure-activity relationships effectively contribute to a higher 
hit rate.
The composition of all 40 hits was determined (table S4). OMP7, 
i.e., cecropin A from Aedes aegypti, is the most prevalent OMP with 
31 of 40 occurrences and exclusively present in the hits with the 
broadest activity. The remaining hits have OMP11, i.e., sarcotoxin 
IA from Sarcophaga peregrine, at their first position. Two other 
cecropin-related OMPs that were included in the second library did 
not appear in the list of hits. Linker 1 (15 of 40) or linker 2 (25 of 40) 
were both well represented, whereas CBD6 was overrepresented (32 
of 40) compared to CBD2 (8 of 40). Sixteen different EADs (of 21 
EADs included in the second library) were identified, showing 
flexibility at this position. Yet, EAD4 was most abundant with 6 of 
40 occurrences.
Table 1. Characterization of seven hits selected after the first screening campaign. The modular composition, growth inhibitory activity against four 
multidrug-resistant A. baumannii strains, and muralytic activity are given for the variants that completely inhibited the growth of at least one strain. The variants 
are ranked according to growth inhibitory effect. A full annotation of the modules is available in table S1. No correlation is observed between growth inhibitory 
activity and enzymatic activity. 
Engineered lysin
Growth inhibitory activity* Muralytic activity 
(U/ml)NCTC 13423 LUH 5875 RUH 875 RUH 134
1D9 OMP7–link1–CBD6–EAD8 +++ +++ +++ +++ 3333
1G7 OMP7–link2–CBD2–EAD9 +++ +++ +++ ++ 2533
1B11 OMP35–link2–CBD1– EAD2 +++ ++ +++ + 4196
1H4 OMP11–link1–CBD6– EAD18 +++ +++ ++ + 1267
1D1 OMP30–link2–CBD2– EAD7 +++ ++ + − 8899
1A10 OMP7–link2–CBD2–EAD10 +++ + ++ − 7366
1H3 OMP30–link2–CBD4– EAD10 +++ − − − 2000
 *The different categories of growth inhibition after 24 hours of incubation at 30°C were classified as follows:   +++, no bacterial growth was 
observed;   ++, bacterial growth with OD655nm between 0 and 0.1;   +, bacterial growth with OD655nm between 0.1 and 0.2;   −, bacterial growth with 
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Identification of a lead variant active against A. baumannii 
in human serum
The most active variants (24 of 40) against three or four of the 
A. baumannii strains (table S4) were withheld to test bactericidal 
activity under more stringent conditions (50% human serum) to 
better mimic human physiological conditions. The most susceptible 
and resistant A. baumannii strains (NCTC 13423 and RUH 134, 
respectively) were spotted after 24-hour exposure to the different 
variants. Five variants (21%) showed a complete absence of surviving 
cells in human serum, with one of them (1D10) completely killing 
both strains (table S5). This engineered lysin (OMP7–linker 1–
CBD6–EAD20) was therefore finally selected as the lead variant.
Large-scale expression of the lead variant yielded 22 mg per liter 
expression volume after purification with nickel affinity chroma-
tography. Minimum inhibitory concentration (MIC) values of the 
lead variant against the four epidemiological A. baumannii strains 
(table S6), a diverse set of 27 pathogenic A. baumannii strains and 
22 Acinetobacter species, including 34 clinical burn wound isolates 
(table S7) ranged between 4 and 24 g/ml (11.8 ± 5.2 g/ml) (20). 
Addition of 0.2 mM EDTA, which acts as a chelator of divalent 
cations present in the outer membrane, further decreases the MIC 
values to 2 to 20 g/ml (4.4 ± 3.6 g/ml). The number of bacteria of 
the four tested strains was reduced with at least 5 logs (Fig. 3). The 
lead variant showed a strain-dependent killing in 90% human 
serum. At a dose of 10× MIC, strain NCTC 13423 was the most 
susceptible strain, reaching a 4.5-log reduction in cell number after 
30 min, whereas the cell number of strains LUH 5875, RUH 875, 
and RUH 134 was reduced between 2.4 and 2.7 logs, respectively. 
The inclusion of 0.2 mM EDTA did slightly enhance the cell log 
reduction to 2.7 to 3.1 logs, respectively (P < 0.05) (Fig. 3).
The lead variant slows bacterial growth and biofilm 
formation in an ex vivo pig skin explant burn wound model
To simulate bacterial growth and biofilm formation on burn 
wounds, a pig skin explant model was established. A standardized 
burn wound bed was created on small pieces of pig skin, followed by 
A. baumannii infection. After bacterial adhesion, a wound bed was 
sprayed with 50 g of lysin. In general, the lead variant could control 
bacterial growth and biofilm formation of all tested strains after 
one single-dose treatment (Fig. 4A). This inhibition resulted in 
a reduction of 2.4 to 3.8 log units in the burn wound model at 
8 hours after treatment compared to the untreated control. This 
reduction was improved when using consecutive dose treatments 








Fig. 2. Growth inhibitory activity of engineered lysins from the first library and the second library. (A) Boxplot distribution of the growth inhibitory activities of 380 
variants (first library: blue) and 188 variants (second library: green) against four epidemiological A. baumannii strains. Both libraries have a similar median value, but the 
second library consistently shows a broader distribution with an increased number of both superior and inferior variants. (B) The percentage of hits inhibiting four 
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obtained after the application of a triple-dose treatment (reduction 
of 4.8 to 5.1 log units 8 hours after treatment). The antibacterial 
activity of the lead variant takes place during the first 5 min after 
protein application with a reduction of 3 and 2 log units against 
A. baumannii RUH 134 and NCTC 13423, respectively (Fig. 4B). 
A. baumannii RUH 134 became the most sensitive strain in this 
ex vivo model of infection. Similar results were obtained in the case 
of a topical wound infection without burning (fig. S4).
DISCUSSION
New antimicrobial discovery platforms are needed to replenish the 
portfolio of antibiotics in response to the rapid emergence of multi- 
and pandrug-resistant bacteria. Whereas the traditional Waksman 
platform got exhausted and suffers from rediscovery, alternative 
platforms to identify antimicrobial (engineered) peptides or anti-
biotics from uncultivatable organisms have been developed (21–25). 
Recent clinical progress up to phase 2 trials has demonstrated the 
Fig. 3. Time-kill assay with the lead variant against four tested A. baumannii strains in buffer and human serum. The used concentration of the lead variant is 1× 
MIC in buffer and 10× MIC in human serum, in the presence or absence of 0.2 mM EDTA. All experiments in buffer reached the detection limit of the assay, as well as all 






(t = 4) (t = 4)
(t = 2)
(t = 0)
Fig. 4. Activity of the lead variant against A. baumannii RUH 134 and NCTC 13423 in an ex vivo pig skin model of burn wound infection. (A) Data represent log of 
CFU per explant after treatment with either a single dose of the lead variant (50 g) at time 0 hour, a double dose of protein (2 hours after the first dose), or a triple dose 
(2 and 4 hours after the first treatment). The control represents the bacterial number without protein treatment. (B) Bars (blue bar: control, green bar: treated with 1D10) 
represent the log of CFU per explant after a single dose of protein (50 g; time 0 min) during a short period of time (60 min). Values correspond to the mean ± SD of four 
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promising prospects of lysins as a broad, novel class of antibacterials. 
Lysins may be identified against each pathogen. In addition, they 
are being further engineered to strengthen their properties for their 
use as antibacterials or to render them active against Gram-negative 
bacteria (7). Yet, an efficient high-throughput approach to con-
struct and identify the most promising engineered lysin is still 
lacking. The approach presented here combines high-throughput 
combinatorial shuffling of lysin modules by VersaTile with parallel 
and iterative antibacterial screening. This approach establishes 
a hit-to-lead development process for engineered lysins to 
saturate the pipeline with new potential candidates for preclinical 
evaluation.
The development and implementation of VersaTile allows the 
generation of a large combinatorial libraries of shuffled engineered 
lysins. In general, a method that allows full combinatorial shuffling 
in a homology-independent way starting from an unlimited num-
ber of parental sequences was inexistent (15). The method of choice 
to create engineered lysins has since long been traditional restric-
tion/ligation. This approach is adequate but becomes increasingly 
cumbersome and laborious when more modules have to be com-
bined or when a large number of combinatorially shuffled variants 
are needed (15). The largest reported libraries of engineered lysins 
using these methods count 49, 126, and 174 variants (9, 10, 12). The 
oldest and most frequently used methods for combinatorial shuf-
fling are based on homologous recombination [e.g., deoxyribonu-
clease (DNase)–based DNA shuffling] but are not applicable for the 
recombination of well-defined, nonhomologous building blocks 
such as the OMPs, linkers, CBDs, and EADs. More recent, homology- 
independent methods such as ITCHY, SCRATCY, SHIPREC, 
SCOPE, SISDC, and USERec have been established (26–32) but 
only partially fill this gap as they all come along with their specific 
drawbacks (e.g., combination of two modules only, highly laborious 
due to multiple PCRs, and no high-throughput combinatorial 
shuffling possible). VersaTile allows us to shuffle nonrelated DNA 
sequences in a rational or combinatorial manner by exploiting the 
inherent ability of a type IIS restriction enzyme to directionally cut 
outside its recognition site with the possibility to freely choose the 
restriction site, as in other methods such as Golden Gate shuffling 
(33). With VersaTile, these restriction sites are embedded in six- 
nucleotide position tags that encode flexible amino acids that intervene 
two modules and are expected to not interfere with the autonomous 
folding and functioning of the modules. On the basis of previous 
lysin engineering work, glycine, serine, and alanine were chosen as 
small amino acids.
Once the repository of tiles was generated, the first library of 
approximately 10,000 variants could be created in a single day. 
The initial hit rate of 2% and enriched OMPs and CBDs provided the 
required input to generate a second library, reusing tiles from 
the existing tile repository. Screening of this second library showed 
an increased proportion of active variants up to more than 21%, 
corroborating the positive contribution (of one) of the implemented 
design rules. The most active engineered lysins from the second 
library were selected to test their in vitro activity in human serum, 
mimicking physiological conditions. This led to the identification 
of 1D10, which decreases the bacterial cell count up to 4.5 log units 
in 30 min in human serum. The identified variant has a broad 
inhibitory activity against Acinetobacter species and prevents bacte-
rial growth and biofilm development in an ex vivo pig skin (burn) 
wound model with A. baumannii.
To date, other (engineered) lysins or peptides derived from 
lysins have been used against A. baumannii, yet they either are not 
active in wounds or human serum or have not been tested (7, 34–37). 
Some native endolysins against Pseudomonas aeruginosa are active 
in low serum conditions (38). In addition, lysocin PyS2-GN4, a 
hybrid of a narrow-spectrum pyocin and a lysin domain, is active in 
human serum with a 4-log reduction after 12 hours (39). Although 
variant 1D10 emerged as the lead candidate from a library with 
clearly defined design rules, the composition of the final lead vari-
ant was unexpected. While its OMP was previously demonstrated 
to be active against A. baumannii species (40), its EAD is derived 
from gp16 of phage BcepC6B. The latter is a VAPGH that locally 
degrades the peptidoglycan layer during infection and has limited 
enzymatic activity compared to phage endolysins (41). Nevertheless, 
the success of a VAPGH can be rationally explained, as a VAPGH 
acts naturally from without and is often resistant to more harsh 
external conditions (pH, temperature, presence of salts, or comple-
ment components as in human serum) (42–45).
Because we screened for growth inhibitory activity with cleared 
lysates, the observed growth inhibitory effects result from the com-
bined effect of intrinsic antibacterial activity and expression yield in 
the lysate. Because of the substantial sequence variation among the 
different modular variants, expression yield is variable as well 
(fig. S5). Variants that perform well for both parameters will emerge 
at the top of the ranking. Otherwise, this also implies that a variant 
with low expression yield but high intrinsic activity can score equally 
well as a variant with high expression yield but low intrinsic activity. 
The lead variant 1D10 was eventually shown to have a combined 
high expression yield (22 mg/liter) and high antibacterial activity, 
including in human serum. Both features are favorable for a pre-
clinical analysis and will reduce the eventual production and purifi-
cation costs. Note that muralytic activity is not an indicator for 
growth inhibitory activity (Table 1). Whereas the muralytic activity 
is mainly determined by the CBD-EAD combination, growth inhib-
itory activity also depends on the OMP efficiency to transfer the 
lysin moiety through the outer membrane. In addition, the OMP 
may also partially contribute to the growth inhibitory activity as has 
been observed before (11).
The presented approach is generic in nature and can be poten-
tially translated to any bacterial target. In addition, each possible 
configuration can be explored (e.g., doubling of OMPs or EADs, 
reversed CBD/EAD order, C- instead of N-terminal position of the 
OMP, and linker variation between CBD and EAD). By extension, 
VersaTile can be used to create DNA libraries that encode variants 
of any modular protein, expanding the protein engineering toolbox 
with many opportunities. Whereas VersaTile has eliminated a ma-
jor technical hurdle in the engineering of lysins, a next hurdle has 
emerged in the throughput of downstream assays. Given the lack 
of methods to analyze all ~10,000 variants, a shortcut trajectory was 
followed through the sequence space comprising all shuffled vari-
ants. The hits from the first screen of randomly selected clones di-
rected us to a subpopulation of the sequence space, where a denser 
search was performed with the second library to end up as close as 
possible to the best variant without outrageous efforts for screening. 
Sequences of the randomly picked clones were only disclosed after 
hit selection, followed by the extraction of structure-activity rela-
tionships between the observed antibacterial activity data and the 
hit sequences. A different screening strategy can be followed in 
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numerous parallel rational assembly reactions as has been applied 
in drug discovery with combinatorial chemistry, a combinatorial 
library with a known systematic variation per position can be creat-
ed. On the basis of a parallel analysis of the antibacterial activity of 
these variants as performed in this study, the positive or negative 
contribution of each tile can be quantitatively calculated based on 
the known sequences of each variant (46–47). Although this re-
quires more experimental work in library construction and library 
screening, variants with further improved antibacterial activity may 
be identified on the basis of those quantitative sequence-function 
relationships. Eventually, a screening technique with a throughput 
that can match up with the library complexity created by VersaTile 
would further leverage the benefits of VersaTile. Much larger librar-
ies could be envisioned. Every additional tile that will be added to 
the repository can be combined with all existing tiles, e.g., if one 
linker tile is added, approximately 5000 more engineered lysins can 
be constructed. Also, other configurations with a different order of 
the modules can be designed, rapidly increasing the total number of 
variants.
MATERIALS AND METHODS
Bacterial strains and growth media
All Acinetobacter strains used in this study and their source are 
shown in table S7. The initial set of four strains comprises reference 
epidemiological clones of the European Union (EU) that have been 
found worldwide and are also referred to as worldwide clones I to III 
[I: RUH 875, II: RUH 134, and III: LUH 5875 (20)]. The fourth strain 
used is the so-called Iraqibacter (“T strain”: NCTC 13423, a battle-
field isolate from casualties of the Iraq conflict) (48). For plasmid 
storage and protein expression, E. coli TOP10 and BL21(DE3)-RIL 
(Agilent Technologies, Belgium) were used, respectively. All 
Acinetobacter (30°C) and E. coli (37°C) strains were routinely grown 
in LB broth (1% tryptone, 0.5% yeast extract, and 1% NaCl) with 
shaking (200 rpm) or on LB supplemented with 1.5% of agar. For 
proper selection of the E. coli clones, LB was supplemented with am-
picillin (100 g/ml), kanamycin (50 g/ml), and 5% (w/v) sucrose.
VersaTile: Preparation of tiles
Depending on the coding sequence length, a tile was constructed 
either by PCR with primers with extended 5′ sequences or by gene 
synthesis [>100 nucleotides (nt)] or generated by primer cassette 
hybridization (<100 nt). Each primer (Integrated DNA Technologies, 
Leuven, Belgium) contained the following necessary parts (listed 
starting from the coding sequence to outward): a distinct position 
tag, a BsaI recognition site (for library construction), and a Sap I 
restriction and recognition site (for tile construction). All enzymes 
were from Thermo Fisher Scientific (Belgium), unless stated other-
wise. For cassette hybridization, the primers were mixed in equal 
ratios (5 M) and incubated at 95°C (5 min), followed by a gradual 
cooldown to room temperature (20°C). Next, the single-stranded 
overhangs were filled in with Pfu DNA polymerase (2.5 U, 72°C, 
10 min). Sequences (>100 nt) were amplified with Pfu DNA poly-
merase (2.5 U) following the manufacturer’s instructions with 
100 pg of phage genomic DNA as template.
Next, the primer cassettes and amplicons were ligated in the sapI 
site of pVTE using the following protocol: 100 ng of pVTE, 50 ng of 
the amplicon/primer cassette, 2 l of T4 DNA ligase buffer, 15 U of 
T4 DNA ligase, and 10 U of Sap I in a total volume of 20 l. Chemical 
competent E. coli TOP10 cells were transformed with the entire 
ligation mixture and plated on LB 1.5% agar, supplemented with 
ampicillin (100 g/ml) and 5% (w/v) sucrose. New tiles were 
confirmed by Sanger sequencing (LGC Genomics, Germany), and 
stocks of 50 ng/l were prepared for each tile.
VersaTile: Preparation of combinatorial libraries
For each position, a tile mixture was made by taking 1 l of 50 ng/l 
of each selected tile. This is repeated for all positions 2, 3, and 4 
separately. Subsequently, 1 l was taken from each tile mixture for a 
certain position and mixed with 1 l from the other tile mixtures 
confining positions 2, 3, and 4. A VersaTile shuffling reaction was 
set up using the following protocol: 1 l of pVTD (100 ng/l), the 
tile mixture (4 l), 1 l of BsaI (10 U/l), 3 l of T4 DNA ligase 
(1 U/l), and 2 l of T4 DNA ligation buffer in a total reaction 
volume of 20 l. The mixture was incubated in the thermocycler 
using the following program: (i) 2 min at 37°C and (ii) 3 min at 
16°C; steps 1 and 2 are repeated 50 times and followed by 5 min 
at 50°C and finally 5 min at 80°C. Chemical competent E. coli 
BL21(DE3)-RIL cells were transformed with the entire ligation 
mixture and plated on LB 1.5% agar, supplemented with kanamycin 
(50 g/ml) and 5% (w/v) sucrose.
Nanopore sequencing and sequence analysis 
of the combinatorial library
This library was sequenced using the MinION sequencer [Oxford 
Nanopore Technologies (ONT), UK]. Initially, the plasmid DNA 
preparation of the combinatorial library was linearized with the 
restriction enzyme Ecl136ii at a site found upstream of the cloning 
site and absent in all but one of the constructs found in position 4 
(hence, no impact on detection capabilities). DNA was then pre-
pared using the one-dimensional (1D) ligation approach of ONT, a 
PCR-free technique that preserves the integrity of the DNA mole-
cules. The resulting library was sequenced on a MinION sequencer 
equipped with an R9.4.1 flow cell for 48 hours. Base calling was 
performed on the data using ONT Albacore v2.3.4, and the resulting 
reads were filtered stringently to map (BWA-MEM) over their 
entire length to the original vector pVTSD, except for the region 
substituted with the VersaTile reaction product (49). Subsequently, 
we analyzed these substituted regions using local alignments with 
the EMBOSS needle tool to verify both the order and the type of 
tiles that made up the constructs (50).
Parallel protein expression and lysate preparation
Overnight cultures were prepared by inoculating single colonies in 
wells of a 96-deep-well plate, each filled with 500 l of LB with 
kanamycin (50 g/ml). The plate was covered with a tape allowing air 
exchange (Brand GmbH, Germany) and shaken (900 rpm) at 37°C 
for 18 hours. A small volume (15 l) from each well was transferred 
to a 96-deep-well plate filled with 500 l of autoinduction medi-
um per well (51). These plates were incubated for 5 hours at 37°C 
(900 rpm). Then, the cultures were incubated at 16°C for 48 hours. 
Cells were harvested by centrifugation (3200g, 30 min, 4°C). The 
pellets containing the cells were further lysed by exposure to chloro-
form vapor above a chloroform-saturated filter for 1 hour at room 
temperature. Afterward, the deep-well plate was inverted to evapo-
rate the residual chloroform. Each lysate was suspended in 500 l of 
20 mM HEPES-NaOH , 150 mM NaCl (pH 7.4), and 1 U of DNase I, 
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resuspension of the pellets, 5 l is spotted onto an LB agar plate to 
confirm complete bacterial lysis. Then, the lysates were cleared by 
centrifugation (3200g, 45 min, 4°C) and stored at 4°C.
Growth inhibition and muralytic assay
Acinetobacter cultures were grown in Mueller-Hinton (MH) broth 
(Becton Dickinson, Belgium) for 18 hours at 30°C. Then, the cul-
tures were diluted in 2× MH broth to an OD625nm (optical density at 
625 nm) = 0.1 (~5 × 108 CFU/ml). From this cell suspension, 50 l 
is inoculated to wells of the microtiter plate, as well as 50 l of 
the cleared lysates. Turbidity is measured at 655 nm after 18 and 
24 hours. Drops of 5 l of the cultures were spotted on LB agar 
plates to analyze bactericidal activity. To test activity in human 
serum, the same protocol was used, except that the cultures were 
diluted in 100% human serum (MP Biomedicals, Belgium). After 
24 hours, the suspensions were diluted in 20 mM HEPES-NaOH and 
150 mM NaCl (pH 7.4) and dropped on LB agar plates.
The substrate for the muralytic assay was produced as described 
previously (52). Briefly, P. aeruginosa PAO1 is grown overnight at 
37°C in an orbital shaker. The next day, fresh LB is inoculated with 
the overnight culture and the culture is grown up to OD600nm = 0.6. 
The culture is spun down and resuspended in chloroform-saturated 
buffer [0.05 M tris-HCl (pH 7.7) and chloroform]. The resuspended 
solution is gently shaken for exactly 45 min. The solution is washed 
twice with phosphate-buffered saline (PBS; pH 7.4) (OD600nm = ±1.5). 
A volume of 270 l of the substrate is mixed with 30 l of the cleared 
lysate. The absorbance (OD600nm) is measured every 30 s for 1 hour 
at room temperature. Then, the muralytic activity was calculated 
using a standardized calculation method (52).
Large-scale protein expression and purification
Recombinant expression of the selected hits was performed as 
previously described (11). Fresh cells [E. coli BL21(DE3)-RIL] were 
inoculated into 0.5 liter of LB medium and grown at 37°C to 
OD600nm = 0.5 to 0.6. Expression was induced with 1 mM isopropyl- 
-d-thiogalactopyranoside (IPTG) at 16°C for 18 hours. E. coli cells 
were lysed in 20 ml of lysis buffer [20 mM NaH2PO4/Na2HPO4, 
0.5 M NaCl, and 50 mM imidazole (pH 7.4)] by freeze-thawing and 
sonication (Q125, Qsonica) on ice. Lysates were cleared (16,000g; 
20 min) and filtered (polyvinylidene difluoride, 0.22-m pore size; 
Novolab, Belgium). Soluble protein was purified with His GraviTrap 
columns (GE Healthcare, Belgium) according to the manufacturer’s 
instructions. The purified lysin was dialyzed against 20 mM HEPES-
NaOH and 500 mM NaCl (pH 7.4) and thereafter against 20 mM 
HEPES-NaOH and 150 mM NaCl (pH 7.4) using Slide-A-Lyzer 
MINI Dialysis Devices (Thermo Fisher Scientific, Belgium). The 
protein concentration was determined spectrophotometrically.
Time-kill assay
A stationary phase culture of the respective strain was diluted (1:10) 
and incubated at 30°C (200 rpm) until mid-exponential phase 
(OD600nm = 0.6). The cell suspension was washed three times with 
20 mM HEPES-NaOH and 150 mM NaCl (pH 7.4) and diluted 
100-fold in 20 mM HEPES-NaOH and 150 mM NaCl (pH 7.4) 
(~106 CFU/ml). A cell suspension of 100 l was incubated at room 
temperature with 50 l of the dialyzed lysin and 50 l of 20 mM 
HEPES-NaOH and 150 mM NaCl (pH 7.4) with/without 0.2 mM 
EDTA. The final concentration of the lead variant (1D10) was 
adjusted for each strain to 1× MIC. After 30 min, cell dilutions were 
plated in triplicate (30°C). The antibacterial activity was quantified 
as the relative inactivation level in log units [log10(N0/Ni), with 
N0 = initial number of untreated cells and Ni = number of residual 
cells after treatment]. Time-kill assays in serum were performed in 
a similar way. Volumes were adjusted to achieve 90% human 
serum, and 10× MIC was used instead of 1× MIC as the final con-
centration of the lead variant (1D10).
MIC assay
The bacterium of interest was grown overnight in MH broth (30°C, 
200 rpm). The overnight culture was then diluted 1:10 and grown to 
OD600nm = 0.6, followed by a 5000-fold dilution in MH broth 
(~2 × 105 CFU/ml). The dialyzed lysin [20 mM HEPES-NaOH and 
150 mM NaCl (pH 7.4)] was added to the cell suspension with a fi-
nal concentration ranging between 0 and 20 g/ml in 2 g/ml steps, 
with and without 0.2 mM EDTA. Blank and controls included the 
bacterium of interest without protein and without EDTA and unin-
oculated broth. The plate was incubated for 18 hours at 30°C, and 
the MIC was determined as the lowest concentration that gave 
complete growth inhibition.
Pig skin explant model of (burn) wound infection
To test the capacity of the lead variant (1D10) to reduce bacterial 
biofilm development, we used a model of wound infection previ-
ously described with some modifications (53). Briefly, pig skin 
was obtained from Minimally Invasive Surgery Center Jesús Usón 
(Cáceres, Spain). Skin was shaved carefully with scissors and razors. 
Moreover, the skin was further cleaned with 70% isopropyl alcohol 
and allowed to dry at room temperature for 30 min. Then, the skin 
explants were obtained by cutting 1 cm × 1 cm. The wound bed was 
created as previously described (51) using a handheld high-speed 
drill with a 4.8-mm high-speed, round, cutter bit (Dremel #192). 
This consistently forms a central “wound bed” of 4.8 mm diameter 
and 1 mm depth. On the other hand, to create the burn wound, a 
stainless-steel tool with a flat end of 4.8 mm diameter was made. To 
create the “burn wound bed,” the end of the tool was burned for 30 s 
and then stamped onto the skin explant for 2 s. Immediately, all 
the skin explants with a wound or a burn wound were sterilized by 
immersion in 70% ethanol, followed by washing in physiological 
saline solution (0.9% NaCl, pH 5.5), and finally ultraviolet steriliza-
tion for 10 min. Sterile explants were then transferred to 24-well 
plates filled with 1 ml of physiological saline solution (0.9% NaCl, 
pH 5.5) supplemented with 0.5% of agar to mimic human body 
conditions.
To prepare the bacterial inoculum, A. baumannii strains were 
grown in shaking LB broth at 30°C. Next, bacteria were diluted to a 
final concentration of 106 CFU/ml in 20 mM HEPES-NaOH and 
150 mM NaCl (pH 7.4). Then, 10 l of this dilution was added to the 
wound or the burn wound bed (~104 CFU per explant) in duplicate 
(four explants per strain per sampling point). Bacteria were then let 
to adhere by incubating 15 min at room temperature. Last, 100 l of 
dialyzed lysin was sprayed onto the skin (final concentration of 
50 g per explant). Samples corresponding to time point 0 were imme-
diately processed after spraying. The rest of the samples were incu-
bated at 37°C with 0.5% CO2. In addition, some samples were treated 
with the protein twice (double-dose treatment, 2 hours after the 
first treatment) or three times (4 hours after the first treatment). 
HEPES-NaOH (20 mM) and NaCl (150 mM, pH 7.4) were used 
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were taken and 1.5 l of proteinase K was added to inactivate the 
protein. Each explant was aseptically transferred to a stomacher bag 
(BagPage, BagSystem, Interscience, St-Nom-la-Breteche, France) 
containing 5 ml of PBS (pH 7.4) and homogenized for 90 s in a 
stomacher (model 80, Seward Medical, London, UK). After ho-
mogenization, dilutions were plated onto LB agar plates. Plates 
were incubated at 30°C for 16 hours. Every time point consists of two 
biological replicates and two technical replicates using two different 
skin explants.
Homology-based modeling of OMPs present in the active 
engineered lysins in the first screening round
To predict the 3D structure of the OMPs that were present in the 
active engineered lysins after the first screening round, we used 
Iterative Threading ASSEmbly Refinement with standard param-
eters (19).
Statistical analysis
The data obtained from the in vitro activity tests (time-kill assays 
and MIC assays) were expressed as the mean ± SD of three repli-
cates. For the ex vivo model of wound and burn wound infection, 
data represent the mean ± SD of four replicates. In all cases, the 
Student’s t test was used to compare the differences between the 
treated and untreated bacterial cultures at a level of significance 
P < 0.05 (SPSS-PC+11.0 software, Chicago, IL, USA). The Pearson 
chi-square with the Fisher’s exact test was used to compare the 
difference in hit rate between the first and iterated combinatorial 
library at a level of significance P < 0.001 (SPSS-PC+11.0 software, 
Chicago, IL, USA). The empirical distribution of tiles obtained with 
nanopore sequencing was analyzed with the package fitdistrplus (X) 
(54), using the chisq.test function available in the R statistical envi-
ronment (55) to compare it to a simulated log normal distribution 
(P > 0.05).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/23/eaaz1136/DC1
View/request a protocol for this paper from Bio-protocol.
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